Cardima Products Featured at the VIIth International Workshop on Cardiac Arrhythmias.Business Editors/Health & Medical Writers FREMONT, Calif.--(BW HealthWire)--Oct. 11, 2001 Cardima(R), Inc. (Nasdaq:CRDM CRDM Control Rod Drive Mechanism CRDM Centre for Rapid Design and Manufacture (Buckinghamshire Chilterns University) CRDM Cumann Rince Dea Mheasa (Irish dancing organisation) ) announced today that three presentations regarding usage of Cardima products and future directions of treating left-sided atrial fibrillation atrial fibrillation Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection. (AF) were presented at the VIIth International Workshop on Cardiac Arrhythmias cardiac arrhythmia n. See cardiac dysrhythmia. Cardiac arrhythmia An irregular heart rate or rhythm. Mentioned in: Holter Monitoring, Stress Test cardiac arrhythmia symposium "New Technology for Pulmonary Vein pulmonary vein n. A vein that carries oxygenated blood from the lungs to the left atrium of the heart. Ablation ablation /ab·la·tion/ (-shun) 1. separation or detachment; extirpation; eradication. 2. removal or destruction, especially by cutting. ab·la·tion n. " on Oct. 9, 2001, in Venice, Italy. Among the manuscripts presented were: -- "Combined Mapping and Ablation Catheter System: Animal Data," prepared by Dr. Sung Chun, Associate Director of Cardiac Electrophysiology and Arrhythmia Services, Stanford University Hospital. -- "Clinical Experience Using a New Style Catheter Technique for Focal AF Ablation," based on the recent successful completion of the first left-sided atrial fibrillation trial using the Cardima REVELATION(TM) Helix(TM) microcatheter, presented by Dr. Thorsten Lewalter, of the University of Bonn, Germany. -- "Ablation of Atrial Fibrillation: Future Directions," which included a discussion of certain Cardima products, presented by Dr. Sanjiv Saksena, Director of Arrhythmia and Pacemaker Services, EHI -- Atlantic Health System -- New Jersey. The VIIth International Workshop on Cardiac Arrhythmias, which was held from Oct. 7-10, 2001, was attended by approximately 1,000 medical professionals. Cardima, Inc. developed its patented, unique series of REVELATION microcatheter systems for the mapping and treatment of AF, which the Company believes is a potential $6 billion market that is poorly served by current treatment alternatives. AF afflicts an estimated 4.5 million people worldwide. The REVELATION series of microcatheters is a minimally invasive, single-use microcatheter for potentially curing AF. Cardima has a Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA study underway in the U.S. for its Revelation Tx linear ablation microcatheter system. The Company believes enrollment in the Phase III trial will be completed at the end of calendar year 2001. Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include the Company's ability to raise additional capital, conduct successful clinical trials, obtain regulatory approvals and gain acceptance from the marketplace for its products. Additional risks are set forth in the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2000 and Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. for the quarters ended March 31 and June 30, 2001, filed with the Securities and Exchange Commission on March 22, May 14 and August 14, 2001, respectively. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion